BIOMERIEUX (EPA:BIM) - bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry identification system: VITEK® MS PRIME

Transparency directive : regulatory news

30/04/2021 07:01

PRESS RELEASE

bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry
identification system: VITEK(r) MS PRIME

Marcy l'Etoile, France - April 30, 2021 - bioMérieux, a world leader in the
field of in vitro diagnostics, has announced the CE-marking of VITEK(r) MS
PRIME, the next generation of the VITEK(r) MS MALDI-TOF1 mass spectrometry
system for routine microbial identification in minutes.

Rapid microorganism identification is a pivotal step in the microbiology
workflow. Over the past decade, MALDI-TOF mass spectrometry has transformed
this process, providing critical information rapidly to clinicians in order to
prescribe more effective antimicrobial therapy.

Including time-saving innovations to deliver faster identification results,
VITEK(r) MS PRIME is a compact benchtop system designed to increase laboratory
productivity for greater impact to patient care.

François Lacoste, Executive Vice President R&D, shared: "We had extensive
input directly from labs as we developed VITEK(r) MS PRIME. The system
incorporates numerous innovative features to make lab life easier, including
improved automation and serviceability, with a robust database that is
consistently expanding with new emerging pathogens and clinically relevant
species. It integrates seamlessly with VITEK(r) 2 for antimicrobial
susceptibility testing and MYLA(r) middleware for data integration and
insights."

"We are really pleased to bring this unique system to labs during the Covid-19
pandemic, when their needs for optimal workflow and efficiency are greater than
ever," said Pierre Boulud, Chief Operating Officer, Clinical Operations,
"VITEK(r) MS PRIME is a powerful innovation that reinforces our offer to
support antimicrobial stewardship.
Unique features like prioritization of urgent samples and continuous 'load and
go' allow for greater efficiency and improved outcomes, which are also key in
the fight against antimicrobial resistance".

With 700,0002 deaths worldwide annually, antimicrobial resistance (AMR) is a
global health priority. Antimicrobial Stewardship (AMS), a key part of the
arsenal to fight resistance, starts with diagnostics. VITEK(r) MS PRIME
positively impacts stewardship programs by providing even faster, highly
accurate pathogen identification making excellent use of the large database of
clinically relevant species to support earlier, targeted therapy.

VITEK(r) MS PRIME, manufactured by bioMérieux is a result of our constant
commitment to support laboratories with tools that provide increased AMS
efficiency and more effective patient therapy.

The commercial launch of VITEK(r) MS PRIME is planned in selected European and
Asian markets in the second half of 2021, extending to the rest of the world
throughout 2022.

ABOUT VITEK(r) MS PRIME AND MALDI-TOF

VITEK(r) MS PRIME is a new generation of the VITEK(r) MS system, launched in
2011 for microorganism identification. VITEK(r) MS PRIME is a Matrix-Assisted
Laser Desorption Ionization Time of Flight mass spectrometer (MALDI-TOF-MS).
The device analyzes material from microbial cultures to provide microorganism
identification. Samples are submitted to multiple laser shots inside VITEK(r)
MS PRIME. The matrix absorbs the laser light and vaporizes, along with the
sample, in the process gaining an electrical charge (ionization). Electric
fields then guide the ions into a vacuum tube which separates them according to
their weight, with the smaller molecules rising up the column faster than the
larger molecules. This "time of flight" creates a series of peaks, which
correspond with the different molecules contained in the organism from the
sample. All of these peaks create spectra unique to that microorganism. By
comparing the spectra to a vast comprehensive library owned by bioMérieux, the
precise microorganism can be identified quickly and easily. VITEK(r) MS PRIME
has been designed to incorporate additional benefits to further enhance the use
of the MALDI-TOF technology.

ABOUT BIOMÉRIEUX'S COMPLETE ANTIMICROBIAL STEWARDSHIP (AMS) SOLUTION

One of bioMérieux's healthcare mission is to help sustain the use of
antibiotic efficiency for generations to come. To support hospitals,
institutions and laboratories with their AMS programs, bioMérieux has a
complete solution covering antibiotic therapy initiation, optimization and
discontinuation. This constantly evolving offer provides labs with timely,
accurate results to adjust therapy, transforms data into actionable insights
and integrates smoothly into any hospital with its flexible partnership
approach. bioMérieux has over 55 years of microbiology expertise with more
than 75% of its R&D directed to AMR/AMS research to ensure the current offer
evolves to meet customers' AMS needs.

ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for over 55 years,
bioMérieux is present in 44 countries and serves more than 160 countries with
the support of a large network of distributors. In 2020, revenues reached
EUR3.1 billion, with over 93% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and
services) which determine the source of disease and contamination to improve
patient health and ensure consumer safety. Its products are mainly used for
diagnosing infectious diseases. They are also used for detecting microorganisms
in agri- food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM - ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: www.biomerieux.com. Investor website:

CONTACTS
Investor Relations
bioMérieux
Franck Admant
Tel.: +33 (0)4 78 87 20 00
investor.relations@biomerieux.com

Media Relations
bioMérieux
Romain Duchez
Tel.: +33 (0)4 78 87 21 99
media@biomerieux.com

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64
lheilbronn@image7.fr

Claire Doligez
Tel.: +33 (0)1 53 70 74 48
cdoligez@image7.fr

REFERENCES
1. MALDI-TOF: Matrix Assisted Laser Desorption Ionization-Time of Flight
2. Tackling drug-resistant infections globally: the review on antimicrobial
resistance chaired by Jim O'Neill 2016

source : webdisclosure.com

BIOMERIEUX's latest news

30/10/2024 07:01

BIOMERIEUX (EPA:BIM) - bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry identification system: VITEK® MS PRIME

Transparency directive : regulatory news

BIOMERIEUX's latest news

Other stories